1. Indonesia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
PT Industri Jamu dan Farmasi Sido Muncul Tbk

PT Industri Jamu dan Farmasi Sido Muncul Tbk

IIDX:SIDO
342.00
IDR
-8.00
(-2.29%)
10.95TMarket Cap
PT Industri Jamu dan Farmasi Sido Muncul Tbk
IDX:SIDO
(Indonesia Stock Exchange)

Recent

price

342.00

P/E

ratio

- -

div

yld

6.44%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
IDR
61.75
72.72
79.12
78.48
72.71
73.74
86.02
85.81
92.12
102.26
112.05
134.82
128.85
118.86
130.64
137.27
- -
Revenue per Share
7.85
11.25
12.82
13.43
13.81
14.54
16.14
17.8
22.13
26.93
31.38
42.28
36.82
31.69
39.03
41.36
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
3.2
5.29
21.54
4.97
13.4
11.96
12.37
12.9
21.83
21.34
26
34.14
36.2
35.6
36
42.9
22.04
Dividend per Share
11.46
17.71
43.16
86.46
86.84
87.17
91.97
96.55
96.77
102.17
107.4
115.72
116.85
112.86
116.26
106.01
101.75
Book Value per Share
11.45
17.7
43.15
86.46
83.82
84.1
88.92
93.16
92.1
97.63
103
111.39
112.54
108.59
111.96
101.57
97.32
Tangible Book Value per Share
30,229
30,229
30,229
30,229
30,229
30,088
29,781
29,993
29,995
29,996
29,768
29,826
30,000
30,000
30,000
29,720
29,385
Basic Weighted Avg Shares
1,866,538
2,198,273
2,391,667
2,372,364
2,197,907
2,218,536
2,561,806
2,573,840
2,763,292
3,067,434
3,335,411
4,020,980
3,865,523
3,565,930
3,919,084
4,079,659
- -
Sales/Revenue/Turnover
17.94
19.97
21.09
18.72
19.88
21.58
21.84
24.47
29.23
33.17
34.28
38.81
35.56
33.87
37.61
37.34
- -
Operating Margin (%)
1,500
1,039
1,037
4,876
7,250
16,036
15,895
11,127
9,991
9,651
8,080
6,511
6,496
9,469
11,262
25,915
- -
Depreciation Expense
237,169
339,935
387,538
405,943
417,510
437,474
480,525
533,799
663,849
807,689
934,016
1,260,898
1,104,714
950,648
1,171,026
1,229,202
- -
Net Income, GAAP
30.08
25.3
24.55
30.33
23.91
21.94
23.61
21.72
23.51
24.78
22.14
21.84
22.2
22.05
22.46
21.93
- -
Effective Tax Rate (%)
12.71
15.46
16.2
17.11
19
19.72
18.76
20.74
24.02
26.33
28
31.36
28.58
26.66
29.88
30.13
- -
Profit Margin (%)
371,770
383,131
747,166
2,042,163
1,679,007
1,523,379
1,578,439
1,420,394
1,175,217
1,307,365
1,492,038
1,701,337
1,653,194
1,604,791
1,792,235
1,472,073
1,391,479
Working Capital
235,858
252,985
- -
- -
- -
- -
- -
- -
- -
- -
4,216
2,385
- -
3,300
- -
- -
- -
LT Debt
346,409
535,344
1,304,651
2,613,606
2,625,180
2,598,314
2,757,885
2,895,865
2,902,614
3,064,707
3,221,740
3,471,185
3,505,475
3,385,941
3,487,844
3,120,434
2,995,174
Total Equity
40.53
40.73
27.95
13.78
12.35
14.26
16.38
17.57
21.35
25.06
27.25
34.8
29.44
25.83
32.17
35.03
- -
Return on Invested Capital (%)
48.75
49.5
32.37
19.64
15.95
16.75
18.05
18.96
22.9
27.07
29.69
37.61
31.63
27.55
34.04
37.2
- -
Return on Capital (%)
90.99
77.1
42.12
20.72
15.94
16.75
17.94
18.88
22.9
27.07
29.72
37.68
31.67
27.59
34.07
37.2
- -
Return on Common Equity (%)

Capital Structure

IDR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4,110
1,591
1,591
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
29,435
29,435
29,435
Market Capitalization
15,895,008
15,159,128
10,949,894

Working Capital

IDR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,986,717
1,972,072
1,604,795
Cash, Cash Equivalents & STI
462,593
769,999
475,644
Accounts Receivable, Net
1,034,423
567,433
539,501
Inventories
466,149
572,820
554,099
Total Current Liabilities
514,644
336,123
213,316
Payables & Accruals
- -
- -
- -
ST Debt
4,110
1,591
1,591
Deferred Revenue
- -
- -
- -

Growth Rates

IDR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.99%
-0.44%
-10.53%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
11.94%
7.36%
4.97%
Sales/Revenue/Turnover
6.6%
4.59%
4.1%
Total Cash Common Dividend
15.1%
11.14%
18.06%

Quarterly Revenue

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,053,423
843,069
730,203
1,292,389
3,919,084
2025
789,105
1,039,600
- -
1,350,676
4,079,659
2026
640,499
826,159
- -
- -
- -

Quarterly Earnings Per Share

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13.02
7.27
5.65
13.1
39.03
2025
7.77
12.34
- -
13.95
41.36
2026
5.05
6.33
- -
- -
- -

Quarterly Dividends Per Share

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
18
36
2025
- -
- -
- -
22
42.9
2026
- -
- -
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
PT Industri Jamu dan Farmasi Sido Muncul Tbk (SIDO.JK) manufactures and markets herbal medicines, supplements, food and beverages, and pharmaceuticals in Indonesia and select international markets. The company offers over 300 products across three main segments: herbal medicine and supplements including flagship Tolak Angin variants (Original, Anak, Flu, Batuk, Sugar Free), Tolak Linu, Esemag, Jamu Serbuk, soft capsules such as Vitamin D3 1000 IU, Vitamin E 300 IU, JSH Capsules, and herbal extracts/essential oils like patchouli oil via PT Semarang Herbal Indo Plant; food and beverages featuring Kuku Bima Ener-G! energy drinks in flavors like grape, orange, coffee, soda milk, and ready-to-drink formats, Susu Jahe ginger milk in Vanilla and Swiss Chocolate, ginger coffee, Vitamin C1000 in lemon and orange, and recent launches such as Natural Vitamin D3+K2, Natural Sari Daun Salam, Anak Sehat Susu in Grape & Strawberry, and Tentrem Teh Tarik; pharmaceuticals encompassing approximately 90 OTC and ethical products like Anacetine, Berlosid, Anabion, and Minyak Telon Cap Tiga Anak produced through subsidiary PT Berlico Mulia Farma. Founded in 1940 in Yogyakarta and established as a company in 1951, Sido Muncul maintains headquarters in Semarang, Central Java, with eight factories, one warehouse, and an extraction plant producing 12,500 kg daily; it operates a vast domestic distribution network via PT Muncul Mekar reaching over 188,000 outlets and 2.5 million points of sale from Sabang to Merauke, plus exports to 30 countries focused on Malaysia, Philippines, Nigeria via Muncul Nigeria Limited, and plans for expansion into Africa and Indochina. Recent developments include Affinity Equity Partners concluding its investment in April 2024 after supporting market leadership and operational enhancements, a share buyback program initiated in March 2025 repurchasing 217 million shares for IDR116 billion with IDR56 billion remaining through December 2025, four new product launches in 6M25, and a 17% YoY export sales increase contributing 9.7% to revenue amid 2024 net profit growth to IDR1.17 trillion.